Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology... see more

TSX:CPH - Post Discussion

Cipher Pharmaceuticals Inc > Acquisition Reaction
View:
Post by retiredcf on Aug 05, 2024 12:14pm

Acquisition Reaction

Cipher Pharma made a major acquisition that they say will double their sales and profits. The new products acquired are also superior to the existing treatment, which has 71% of the USA market, so lots of room there for growth, plus they plan to get approval in Canada and make a deal for ex-North America sales. They also have their drug for toenail fungus, a big market, set to produce final results in about 6 months, with sales expected starting in 2026. This looks like a good growth stock to me, trading at a cheap valuation, given the profit from the new products, and I am wondering what your take is on the acquisition and the stock?

The acquisition looks quite good, and the stock remains cheap at 13X earnings despite its 88% gain this year. The valuation looks OK and adding new products with high potential certainly makes sense. CPH has the financial capacity, going into the deal with a strong balance sheet. Analysts have not updated their models yet, and going into this deal CPH was expected to see lower EPS in the next 18 months. But the deal changes its growth rate and size of the company, which should get it a better valuation, over time. It is still fairly small, and not all deals succeed, but the news looks quite good to us. (5iResearch)
Comment by mjh9413 on Aug 09, 2024 12:10am
All sounds good at first blush but I see the comment in NR that "Spinosad, a topical treatment for both head lice and scabies. There are currently no generic alternatives for these products" but I also see Good Rx has a voucher for a generic version. The costs of both are 'interesting'. Also contrast permethrin cost, whch they say is also used for scabies not (lust) head lice ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities